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Abstract: Alkyl methanesulfonates have been highlighted as potential genotoxic impurities (PGIs). A sensitive LC/MS/MS method 
was developed and validated for the determination of Alkyl methanesulfonate impurities in Emtricitabine API (active pharmaceutical 
ingredient). LC/MS/MS method on Zorbax SB C18 column (150 × 4.6 mm i.d.), 3.5 µm, with electrospray ionization (ESI) in multiple 
reaction monitoring (MRM) mode was used. The proposed method was specific, linear, accurate, rugged and precise. The calibration 
curves showed good linearity over the concentration range of 0.0025 µg/ml to 0.3 µg/ml the correlation coefficient was .0.999 in each 
case. Method had very low limit of detection (LOD) and limit of quantification (LOQ) as 0.3 µg/g and 0.4 µg/g respectively for both the 
analytes. Accuracy was observed within 80%–120% for both the analytes. This method can be further extended a good quality control 
tool for low level quantitation of Alkyl methanesulfonate impurities in other API.
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Introduction
Emtricitabine  is  a  nucleoside  reverse  transcriptase 
inhibitor for the treatment of HIV (Human immu-
nodeficiency  virus)  infection  in  adults.  The  drug 
works  by  inhibiting  reverse  transcriptase  enzyme 
which copies HIV RNA (Ribonucleic acid) into new 
viral  DNA  (Deoxyribonucleic  acid).  Emtricitabine 
is often administered in combination with   Tenofovir 
  disoproxil  fumarate,  the  maximum  daily  dose  of 
Emtricitabine is 0.2 g per day.
Synthetic starting materials and intermediates are 
reactive by design and may occur as impurities in the 
final API. The nature of this chemical reactivity can 
often  translate  into  biological  reactivity  and  these 
materials  can  often  be  mutagens  or  carcinogens. 
Many times it has been established that due to high 
chemical reactivities the fate of the several alkylating 
agents precluded their retention within the final API 
especially if their formation was separated from the 
final API by several synthetic steps.
Methyl methanesulfonate (MMS) and ethyl meth-
anesulfonate (EMS) are often used during manufacture 
of pharmaceuticals, either as a counter-ion to form 
a salt, as acid catalyst or as a result of protecting 
group  removal  during  the  synthesis.  However,  the 
presence  of  alcohol  either  in  any  of  the  stages  of 
synthesis, or the crystallization stage of the salt may 
cause the   formation of sulfonic acid esters which are 
  considered to be potential genotoxic agents.1 These 
potential genotoxic impurities (PGIs) are known to 
induce genetic mutations or chromosomal aberrations 
and are reported as known carcinogens in rats and 
mice.2  The  potential  presence  of  these  genotoxins 
has attracted the attention of regulatory authorities. 
European Medicines Agency’s (EMEA) Committee 
for   Medicinal products for Human use (CHMP) has 
published  guidelines  regarding  limits  of  genotoxic 
impurities.3 Recently, in 2008 US FDA (United States 
Food and drug administration) has also come up with 
the draft guidelines on genotoxic and carcinogenic 
impurities in drug substances and products.4 These 
guidelines describe ways to reduce the potential life-
time cancer risk associated with patient exposure to 
genotoxic and carcinogenic impurities and the ways 
to reduce them. A maximum daily exposure target 
of 1.5 µg per day [acceptable Threshold of Toxico-
logical  Concern  (TTC)]  is  recommended  in  these 
guidelines.3–5
Based on the maximum daily dosage of Emtricit-
abine MMS and EMS are required to be controlled at 
a   combined limit of 7.5 µg/g in the API.
Due to the increasing concern from the   regulatory 
perspective in relation to the potential hazards, there 
has been a general renaissance and increased number 
of analytical techniques, mainly gas chromatographic 
methods utilizing both flame ionization detector and 
mass spectrometric detectors are reported in   literature 
for the determination of alkyl sulfonate impurities. 
But these methods have drawbacks of either higher 
limit  of  quantitation  (LOQ)  or  limit  of  detection 
(LOD).  Capillary  GC/MS  (Gas  chromatography-
mass  spectrometry)  method6  for  the  determination 
of EMS has been reported within the linear range of 
50–200  µg/g.  GC-FID  (gas  chromatography-flame 
ionization detector) method7 have been reported for 
the determination of alkyl methanesulfonates but this 
method had the drawback of higher limit of detection. 
Moreover, GC-FID not being a very selective and spe-
cific technique. Direct injection techniques both on GC 
and HPLC (high performance liquid chromatography) 
are also reported in the literature. Quantitative GC/
MS method involving DB-WAX column, using single 
ion-monitoring mode (SIM) have been reported using 
m/z of 78.98 as the common peak. GC-FID method 
using DB-WAX column8 for determination of residual 
MMS and EMS suffered from the drawback of matrix 
interference  due  to  build  up  of  residual  API  and 
required frequent replacement of injection liner after 
20 min, further the method had higher LOD and LOQ 
of 1 µg/g and 5 µg/g respectively.
Extraction based studies have also been reported to 
deal with the matrix related issues and aimed to clean 
up the matrix. The frequently used sample   preparation 
technique being the liquid-liquid   extraction (LLE)9 
for  pre-concentration  and  matrix  removal.  LLE 
  preconcentration with GC/MS detection have been 
reported  for  determination  of  MMS  and  EMS  but 
these  methodologies  are  labour-intensive  and  are 
prone to interferences from other solvents are well as 
emulsion formation. Moreover, the resulting sample 
preparation method requires extra validation. Limit 
test  method  using  sample  preparation  techniques 
like  SPME  (solid  phase  micro  extraction),  LPME 
  (liquid phase micro extraction) and SPE (solid phase 
extraction) followed by GC/MS have been reported,9 
with  a  very  high  limit  of  detection  of  5  µg/g. Determination of MMS and eMS in emtricitabine API using LC/MS/MS
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Other than direct analysis,   derivatization methods10,11 
are also been reported for the determination of MMS 
and  EMS  involving    derivatization  with    aqueous 
sodium thiosulphate and with pentaflurothiophenol 
but these are often cumbersome to perform. Most 
of  the  GC/FID  and  GC/MS  method  reported  had 
drawbacks  of  matrix  interferences  and  had  higher 
LOD  and  LOQ.  The  required  low    tolerance  of 
these   impurities   presents a major challenge for the 
  pharmaceutical   industry. Although there are a num-
ber of different detection techniques available, these 
have to be chosen   carefully on a case-by-case basis. 
HPLC with Ultra violet (UV) detector is not useful 
in many cases for the low level quantitation of the 
analytes. The major issues are sensitivity, selectivity 
and the problems related to matrix interferences in 
the APIs. Appropriate controls need to be built into 
the   analytical procedures to ensure confidence in the 
results generated and methods should be such that 
they  are  easily  transferred  to  the  quality  control 
  environment. It is therefore imperative that the ana-
lytical methodology must be robust. In view of these 
practical issues inherent with the reported methods 
and  increasing  concern  from  the  regulatory  per-
spective in relation to the   potential hazards of alkyl 
sulfonate impurities, the biggest challenges facing the 
pharmaceutical   industry is the need for development 
of extremely sensitive and robust analytical meth-
odologies  that  can  adequately  monitor  potentially 
genotoxic impurities at very low levels.
The proposed LC/MS/MS (liquid   chromatography/
mass  spectrometery/mass  spectrometery)  method 
for  determination  of  MMS  and  EMS  is  a  direct, 
  sensitive and robust involving no laborious   sample 
  preparation steps. This method has many   advantages 
over  the  method  reported  in  the  literature  in 
terms  of    specificity,  accuracy  and  reproducibility 
involving direct   analysis and compared to laborious 
  sample preparation   techniques. Matrix interference 
in  dealt  in  method  by  utilizes  a  diluent  in  which 
  Emtricitabine API is insoluble and the analytes are 
exactable from the API matrix. The proposed method 
involves MRM mode for quantification of MMS and 
EMS with   electrospray ionization to achieve very 
low LOD and LOQ. Further, this method does not 
require switching-valve as the API is insoluble in the 
selected and avoid the introduction of matrix into the 
mass detector.
experimental
reagents and chemicals
HPLC-grade  acetonitrile  was  purchased  from 
J T backer (Phillipsburg, USA); formic acid was pur-
chased from Sigma-Aldrich (Milwaukee, WI), purified 
water   collected through Milli-Q water   purification system 
(Millipore, Bedford, MA, USA).   Reference   substances 
MMS and EMS were   purchased from   Sigma-Aldrich 
(Milwaukee, WI) and Emtricitabine API samples were 
obtained from Ranbaxy Laboratories Ltd (India).
Instrumentation
Chromatography
The LC system used was an Agilent 1100 series LC 
system (Agilent Technologies, Waldbronn,   Germany) 
consisting of a 1100 series pump with a   degasser, a 
  temperature controlled micro-well plate, auto   sampler 
and a column compartment. The   analytical column 
was a Zorbax SB C18 (150 × 4.6 mm) 3.5 µm. The 
mobile  phase  consisted  of  premixed  and  degassed 
solution  of  Formic  acid  0.1%  (v/v  in  water)  and 
  acetonitrile in the ratio of [70:30] [v/v]. The flow rate 
was 0.2 ml/min and the run time was 20 minutes. 
Column oven temperature was maintained at 50 °C. 
Injection was 50 µL. The control of the HPLC system 
and data collection was by Empower software.
Mass spectrometer
An  ion  trap  mass  spectrometer  (4000  Q-trap  of 
Applied  Biosystems,  Switzerland)  equipped  with 
positive ion electospray ionization probe was operated 
in split less mode. The control of the system and data 
  collection was by Analyst 1.4.1 (Applied Biosystems). 
MRM transitions m/z 110.9 . 78.8 and 125.1 . 97.1, 
were selected for quantification of MMS and EMS 
respectively.  Typical  operating  conditions  were  as 
follows:  Ion  spray  voltage  was  kept  as  5500V  and 
source  temperature  250  °C.  Declustering  potential 
applied was 45V for MMS and 25V for EMS. Collision 
energy and Collision cell exit potential were 15, 15 and 
12, 10V respectively.
Validation study
The developed mass method for the determination 
of MMS and EMS in one API was validated. The 
  linearity was evaluated by preparing and analyzing 
nine calibrators of each analytes in the concentration Kakadiya et al
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range 0.0025–0.3 µg/ml using the appropriate MRM 
transition. The slope, intercept and regression coef-
ficient were determined by the least squares   linear 
regression  analysis.  System  precision  was  done 
by injecting six replicate injections of the standard 
  preparation. The limit of quantitation was calculated 
on the basis of the lowest concentration of each ana-
lytes that gives percentage relative standard deviation 
(%RSD)  ,10%. The  precision  and  accuracy  were 
evaluated by spiking each analytes and determining 
the %RSD , 10%. Stability of analytical solution 
was evaluated at 10 °C for 5 hours. Ruggedness study 
was performed by different scientist using different 
column by spiking each analytes and determining the 
%RSD , 10%.
standard and sample preparation
Standard preparation
Stock  standard  solution  of  MMS  and  EMS  was 
prepared in acetonitrile of concentration 0.75 µg/ml. 
Final standard solution was prepared in mobile phase 
of 0.15 µg/ml concentration.
Sample preparation
API was prepared 100 mg/ml (accurately weighed) in 
acetonitrile and filtered this sample solution through 
0.45 µ polytertafluoroethylene (PTFE) filter. 1 ml of 
this filtrate’s transferred to a 5 ml volumetric flask 
and made up to the mark with mobile phase.
sample Analysis
Accurately  weighted  API  powder  was  carefully 
transferred in a 20 ml volumetric flask. The pow-
der was mixed with 10 ml of acetonitrile and soni-
cated for 5 minutes. The mixture was filtered through 
0.45  µ  PTFE  filter  and  the  filtrate  solution  was 
collected in a 5 ml volumetric flask. Mixed 1 ml of 
this filtrate and 1 ml of mobile phase for final sample 
concentration. A 50 µL aliquot was injected into the 
mass spectrometer.
Results and Discussion
Method optimization parameters
Optimization of sample preparation
Sample  preparation  is  an  important  part  of  the 
  genotoxic impurity analysis analysis, because matrix 
effects in trace analysis are magnified, causing loss of 
sensitivity, abnormal recovery and analyte   instability. 
In order to avoid complexity in the sample preparation 
procedure, diluent selection was done in such a way in 
which Emtricitabine had no or minimum solubility and 
at the same time analytes were completely extractable 
from the matrix. As the quantitation was required to be 
done at very trace, sample concentration was required 
to be increased in order to achieve lower detection 
levels. Sample preparations were done in acetonitrile 
and in mobile phase as diluent. It was observed that in 
acetonitrile API was not soluble however MMS and 
EMS has very good solubilities. In diluent as mobile 
phase both API and MMS and EMS were soluble, but 
due to matrix interference of the API low recoveries 
were observed for MMS and EMS. Acetonitrile alone 
was also evaluated as diluent but was found to be not 
suitable due to lower responses of the analytes and 
bad  peak  shape.  Therefore,  during  sample  prepa-
ration  acetonitrile  was  added  initially  followed  by 
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Figure 1. Linearity plot of MMS in the concentration range of 0.0025 µg/ml 
to 0.3048 µg/ml.
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Figure 2. Linearity plot of eMS in the concentration range of 0.0025 µg/ml 
to 0.3015 µg/ml.Determination of MMS and eMS in emtricitabine API using LC/MS/MS
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dilution in the mobile phase. The purpose of adding 
acetonitrile was to remove matrix effect of the API. 
In acetonitrile, Emtricitabine was insoluble and the 
analytes (MMS and EMS) had very good solubilities. 
This resulted in removal of the matrix and at the same 
time  optimum  extraction  of  the  analytes,  resulting 
in proper peak shapes and recoveries in the range of 
83.50 to 101.22% and 80.57 to 90.04% for MMS and 
EMS respectively.
column selection and separation
For adequate retention and separation of MMS and 
EMS different columns like ACE C18,   Kromasil C18 
and Zorbax C18 of different dimensions were evaluated. 
On ACE C18 and Kromasil C18 early   elution, blank 
interference and inadequate separation of analytes was 
observed (refer Table 3). However, on Zorbax C18 
column separation and response for both MMS and 
EMS was found to be suitable. Different composition 
of mobile phase using ammonium formate and formic 
acid with acetonitrile were studied. Good separation 
and responses were observed using formic acid 0.1% 
(v/v in water) and acetonitrile in the ratio of 70:30 (v/v) 
with column oven temperature of 50 °C at a flow rate 
of 0.2 mL per min. Under these conditions the reten-
tion time of MMS and EMS were observed to be about 
9 and 12 min respectively.
Optimization of Mass  
spectrometric parameters
Choosing a detection method is the most   important 
part  of  pharmaceutical  analysis.  From  the 
  instrument  simplicity,  stability  and  availability 
point of view HPLC-UV and GC-FID were first 
evaluated. However, on these techniques sufficient 
sensitivity  for  the  trace  level  analysis  of  MMS 
and EMS was not achieved. In view of this, sensi-
tive and   specific mass spectrometric detection was 
evaluated in MRM mode. MRM technique relies 
on measurement of the   parent/daughter couple of 
an analyte in the   mixture. This mode permits sig-
nificant enhancement of   selectively and sensitivity 
for screening and   quantification. For MRM quan-
titation, specific mass transitions (daughter ions) 
Table 1. Limit of Quantitation (LOQ) and Limit of Detection 
(LOD) for MMS and eMS.
conc. MMs eMs
LOQ LOD LOQ LOD
μg/mL
ppm or μg/g
0.0080
0.4
0.0060
0.3
0.0081
0.4
0.0061
0.3
Injection no. Area counts
1 3411 3031 5687 5414
2 3467 2730 5233 5709
3 3476 2440 6682 5378
4 3040 3308 5219 4574
5 4090 1623 5397 4773
6 3564 3449 5647 4433
Mean 3508 2764 5644 5047
sD 339 670 546 521
RsD (%) 9.66 24.24 9.67 10.32
Table 2. Accuracy of MMS and eMS at different spiking concentrations.
Recovery 
level
MMs eMs
Amount 
added 
(μg/g)
Amount 
recovered 
(μg/g)
%  
Recovery
Amount 
added 
(μg/g)
Amount 
recovered 
(μg/g)
% 
Recovery
50% rec-1   3.751   3.132   83.50   3.670 2.957 80.57
50% rec-2   3.777   3.513   93.01   3.696 3.101 83.90
50% rec-3   3.761   3.303   87.82   3.680 3.105 84.38
100% rec-1   7.568   7.018   92.73   7.405 6.432 86.86
100% rec-2   7.496   6.958   92.82   7.335 6.255 85.28
100% rec-3   7.543   6.873   91.12   7.381 6.221 84.28
150% rec-1 11.272 10.614   94.16 11.030 9.547 86.55
150% rec-2 11.268 10.868   96.45 11.026 9.723 88.18
150% rec-3 11.338 11.476 101.22 11.094 9.989 90.04
Mean   92.54 85.56
sD     4.995   2.747
RsD (%)     5.40   3.21Kakadiya et al
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  fragments for MMS (m/z 110.9) were observed to 
be at m/z 78.8 and m/z 69.9. For EMS (m/z 125.1) 
the major fragment ions were observed at m/z 97.1 
and m/z 115.0. For MRM quantitation combina-
tion of   precursor ion and product ion were selected 
for both MMS and EMS on the basis of response. 
For MMS the MRM transition selected was 110.9 
(parent mass of MMS) → 78.8 (fragment mass of 
MMS), as this was the most intense transition. In 
case of EMS the MRM transition of 125.1 (parent 
mass of EMS → 97.1 (fragment mass of EMS) was 
selected on the basis of response.
Validation
Validation  was  necessary  before  the  application 
of the developed mass procedure to the commer-
cial products. The developed mass method for the 
  determination of MMS and EMS in Emtricitabine 
API  was  validated. The  linearity  was  established 
by plotting the peak area counts of an individual 
  analytes versus   concentration of each analytes in 
the concentration range 0.0025 µg/ml to 0.3 µg/ml. 
The slope, intercept and regression coefficient were 
determined  by  the  least  squares    linear  regression 
analysis.  Linearity  correlations  of  the  peak  area 
counts and concentration of both the analytes was 
Table 3. Comparison of various hPLC columns for sepa-
ration and elution of MMS and eMS.
name of HpLc 
columns 
Retention time, separation and 
response behavior of MMs  
and eMs
ACe C18 early elution (peak eluting at the  
void volume)
Kromasil C18 Blank interference and broad  
peak shapes for MMS and eMS
Zorbax C18 Separation, good retention and 
response for both MMS and eMS
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Figure 4. A) MrM scan of MMS in Blank. B) MrM scan of eMS in 
Blank.
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were  selected  for  MMS  and  EMS  by    preparing 
standard solution of the analytes in acetonitrile and 
directly infusing into the ESI probe using Harvard 
syringe pump. The ion source temperature and ion 
spray  voltage  were  optimized  as  at  250  °C  and 
5500V  respectively.  Declustering  potential  and 
collision energy used for collision induced disso-
ciation were optimized as 45V and 25V for both 
MMS and EMS. The Collision cell exit potential 
value  was  optimized  as  15V. The  MRM  experi-
ment  was  accomplished  by  specifying  the  par-
ent  mass  of  the  analytes  (both  MMS  and  EMS) 
for  MS/MS  fragmentation  and  then  specifically 
monitoring for a single fragment ion. The major 
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Figure 3. A) MrM scan of MMS in standard preparation. B) MrM scan 
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Figure 5. A) MrM scan of MMS in sample solution. B) MrM scan of eMS in sample solution.
achieved  r2:0.999  as  represented  graphically  in 
Figures 1 and 2. The LOQ was calculated on the 
basis of the lowest concentration of each analytes 
that gives %RSD ,10%. The LOD 0.3 µg/g and 
LOQ was 0.4 µg/g for both the analytes. Data sum-
marized in Table 1. System precision was 3.82% for 
MMS and 5.12% for EMS. MMS and EMS were not 
found in the Emtricitabine sample hence method pre-
cision and accuracy experiments were   performed by 
  spiking each analyte and determining the %RSD. The 
%RSD for six replicate preparations was observed as 
2.39% and 3.83% for MMS and EMS   respectively. 
  Recovery of the spiked amounts of   analytes were 
calculated,  the  mean  recovery  percentages  were 
observed to be in the range of 88.11–97.28 for MMS 
and 82.95–88.26 for EMS indicating good correla-
tion  of  the  calculated  and  added  concentrations. 
Data summarized in Table 2. Stability of analyti-
cal solution was evaluated at 10 °C for 5 hours and 
the solution was observed stable during this period. 
Ruggedness  study  was    performed  by    different 
  scientist  using    different    column.  The  %RSD  for 
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Figure 6. A) MrM scan of MMS, spiked at 100% level in sample solution. B) MrM scan of eMS, spiked at 100% level in sample solution.publish with Libertas Academica and 
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  ruggedness study was observed as 2.66% for MMS 
and 2.16% for EMS. The derived values indicate 
good reproducibility and sensitivity of the method.
conclusion
A direct tandem mass spectrometric method was 
described for screening and quantification of MMS 
and  EMS  in  the  API.  The  MS-MS  profile  was 
more  sensitive  and  specific  than  MS  profiles  for 
the detection of any undeclared MMS and EMS 
in the API. Furthermore, the method was   accurate 
and  reproducible  for  measurement  of  MMS  and 
EMS detected in the API. The high levels of MMS 
and  EMS  in  the API  might  be  dangerous  if  this 
  product  was  not  properly  tested  by  drug  quality 
control   laboratories. The described method pres-
ents a highly reliable technique for rapid detection 
of Genotoxic impurities in the API with accurately 
and precisely.
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